Amylase (Pancrelipase)

Summary

Amylase (Pancrelipase) (CHEMBL1201648) is an approved enzyme; indicated across 3 conditions including diarrheal disease and borderline personality disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• Indications: 3 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201648
Name	Amylase (Pancrelipase)
Type	Enzyme
Max phase	4

Also known as: Amylase (pancrelipase), E1100, AMYLASE (PANCRELIPASE)

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
diarrheal disease	3	MONDO:0001673	HP:0002014
borderline personality disorder	2	MONDO:0001156	HP:0012076

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).